[A19-94] Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V
Last updated 17.02.2020
Commission awarded on 15.11.2019 by the Federal Joint Committee (G-BA).
Muscles, bones and joints
Children aged 5 years and older and adolescents with active, autoantibody-positive SLE with a high degree of disease activity despite standard therapy
Added benefit not proven due to lack of interpretable study data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.